SCHEMBL26328366

SCHEMBL26328366

Cc1ccc([C@@H]2CC2C(=O)N2CCN(c3cc(C)ccc3C)CC2)cc1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.69
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
TSHR P16473 3/20 0.55
ALDH1A1 P00352 3/20 0.53
KDM4E B2RXH2 1/20 0.53
USP2 O75604 1/20 0.53
HSD17B10 Q99714 1/20 0.53
SIGMAR1 Q99720 1/20 0.52
LMNA P02545 4/20 0.50
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPT P10636 4/20 0.48
TDP1 Q9NUW8 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
MC4R P32245 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26328340 1.00 AR (0.69) ARMEN1KMT2ATSHRALDH1A1
SCHEMBL26327879 1.00 AR (0.69) ARMEN1KMT2ATSHRALDH1A1
SCHEMBL26327922 0.93 AR (0.80) ARMEN1KMT2ATSHRALDH1A1
SCHEMBL18069683 0.93 AR (0.78) ARMEN1KMT2ATSHRALDH1A1
SCHEMBL26327856 0.91 AR (0.84) ARMEN1KMT2ATSHRALDH1A1
SCHEMBL20673768 0.91 AR (0.64) ARMEN1KMT2ATSHRALDH1A1
SCHEMBL26328342 0.91 AR (0.84) ARMEN1KMT2ATSHRALDH1A1
SCHEMBL26328339 0.91 AR (0.84) ARMEN1KMT2ATSHRALDH1A1
SCHEMBL26327882 0.89 AR (0.65) ARMEN1KMT2ATSHRALDH1A1
SCHEMBL26328332 0.89 AR (0.65) ARMEN1KMT2ATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11766433-B2 Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11766433-B2 Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer AR, NR0B1, NCOA3 AR 1/4885MEN1 3572/4885KMT2A 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.